Fosun International Climbed — But the 72% Discount to NAV Is the Real Story

In an ironic move, Fosun International (0656.HK) was punished in March 2026 after warning its 2025 annual loss could widen fivefold to roughly RMB 23.4 billion. Shares dropped 5% in the worst intraday selloff since October 2024. The market heard "property impairments" and reacted like it was getting margin calls from Evergrande.

Two months later, the company issued a positive profit alert. First-half 2026 profit is projected at RMB 1.5 billion to RMB 1.8 billion — a 127% to 172% year-on-year jump. The stock has since climbed back to HKD 5.09, up roughly 7.4% in a single session on August 7th. The rebound is real, but the disconnection between price and underlying value hasn't narrowed nearly enough.

The market is still pricing Fosun as a China property bag of tricks. The stock trades at HKD 5.09 against a management-stated net asset value of HKD 18.1 per share. That's a 72% discount to NAV. If core businesses are actually recovering — and the July profit alert suggests they are — the math says the market has barely moved the needle.

Here's what matters, in order of importance.

1. The RMB 23.4 billion loss was non-cash and non-recurring.

The March 2026 profit warning covered fiscal 2025, when Fosun booked impairment provisions on real estate projects (about 55% of the total) and goodwill plus intangible assets from non-core segments (about 45%). Chairman Guo Guangchang called it "prudent accounting, not a reflection of operational issues" and described it as repairing the roof on a sunny day. The write-downs did not affect operations or cash flow. Net assets after the impairment still sat around RMB 95 billion, versus RMB 118 billion before. That's a clean balance sheet relative to a HKD 41 billion market cap.

The key question for investors is whether impairments like this repeat. Fosun's stated strategy is to exit low-profitability and underperforming assets, and the company has been actively trimming non-core holdings. If that discipline holds, the RMB 23.4 billion charge is a one-time base effect — the kind that makes next year's numbers look dramatically better without any actual operational improvement.

2. Core businesses are growing into that cleaner base.

The 1H2026 profit alert breaks out four core subsidiaries, all ahead of prior-year figures:

• Fosun Pharma (healthcare): Q1 revenue of RMB 10.07 billion, up 6.9% year-on-year; net profit up 13.9%, or 22% excluding non-recurring items. The drug arm closed global exclusive licensing deals with Pfizer (potential value over US$2 billion) and Clavis Bio (potential payments up to US$7.25 billion).
• Pramerica Fosun Life Insurance (wealth): H1 2026 net profit of RMB 786 million, already exceeding its full-year 2025 profit.
• Hainan Mining (intelligent manufacturing): H1 2026 net profit of RMB 470–550 million, up 68–96% year-on-year. Profit in the first six months already surpassed the full year of 2025.
• Yuyuan (consumer/tourism): H1 2026 net profit forecast at RMB 120–170 million, up 91–171%.

Four subsidiaries generated RMB 128.2 billion of Fosun's total RMB 173.4 billion revenue in 2025 — that's 74% of the top line coming from the businesses the company is actually keeping. The conglomerate discount argument only works if the sum of the parts doesn't grow faster than the market expects. Right now, every core segment is accelerating.

3. The Club Med IPO is the catalyst the market hasn't priced in.

Fosun is planning a Hong Kong listing for its resort operator Club Med, with BNP Paribas, HSBC, and JPMorgan acting as underwriters. The deal could raise at least US$500 million and is targeted for late 2026 or early 2027. Club Med CEO Stephane Maquaire has confirmed the timeline.

This matters for two reasons. First, an IPO sets a public market valuation on a subsidiary the market currently values at a deep conglomerate haircut — potentially unlocking value that's invisible in the parent company's share price. Second, Fosun originally acquired Club Med in 2015 for roughly US$1.1 billion. A US$500 million-plus IPO would price the business at or above what Fosun paid, after a decade of integration and expansion across 70 resorts worldwide.

Club Med's operational momentum supports the listing. During the 2026 Spring Festival, average occupancy across five premium all-inclusive resorts in China reached 90%. Atlantis Sanya saw revenue jump 20% year-on-year during the holiday period, and inbound tourist numbers surged 90% during the Labour Day holiday. These are the kind of numbers that attract IPO investors.

4. Management is putting skin in the game.

Between March 30 and July 10, 2026, Fosun repurchased approximately 53.4 million shares for HKD 216 million. Separately, the controlling shareholder and management team have committed to increasing their holdings. That's the credibility signal this thesis needs — management buying shares while the stock trades at a 72% discount to NAV, not just when it's already rallying.

The dividend policy is also shifting. The target payout ratio is rising from 20% to 35%, with expected dividends of no less than HKD 1.5 billion. Management has laid out medium-term targets of RMB 10 billion in annual profit, RMB 60 billion in recovered cash, total debt below RMB 60 billion, and an investment-grade credit rating. S&P has affirmed the outlook as Stable.

The risk.

China's property sector remains in a prolonged downturn, and Fosun's remaining real estate exposure is real even after the impairments. If the downturn deepens and drags into the core businesses through consumer weakness or credit stress in the insurance book, the recovery narrative breaks. The 72% NAV discount exists for a reason — conglomerates in China have been discounted for years, and a discount can persist longer than most investors are patient enough to hold. The stock may need to find a more stable bottom before investors dive in, especially if broader Hong Kong market sentiment turns risk-off.

The closing number.

At HKD 5.09, Fosun trades at 28% of its stated NAV of HKD 18.1 per share. Even applying a generous 40% conglomerate discount — which would value the stock at HKD 10.86 — the current price implies the market is writing off more than half the asset base as worthless. The 1H2026 profit alert, accelerating core business results, the upcoming Club Med IPO, and active buybacks don't prove the discount will close. They do make it look like the market is focusing on a one-time accounting charge while ignoring four growing businesses, a US$500 million-plus listing catalyst, and management buying at current levels. The disconnect between the narrative and the forward math is still wide open.